Janux and BMS Partner on Tumor-Activated Cancer Therapy
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
NEW YORK and VIENNA – October 31, 2025 — HOOKIPA Pharma Inc. (OTC: HOOK) announced the completion of the...
